复合性肝病的新兴疗法和治疗目标:NASH
M Elizabeth Sobhia1, Sonia Kumari1, Harish Kumar1
1Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Sector - 67, S. A. S. Nagar (Mohali), Punjab, 160062, India.
非酒精性脂肪肝炎 (NASH) 是一种严重的肝病. 本综述总结了有关NASH病因,治疗和药物点的研究,强调了开发新疗法的进展和挑战.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 药理学和药物发现
背景情况:
- 非酒精性脂肪肝炎 (NASH) 是一种进展性肝病,其特征是脂肪,炎症和纤维化.
- 这是一种严重的非酒精性脂肪性肝病 (NAFLD),可能导致肝细胞癌 (HCC).
- 炎症媒介在从简单的脂肪肝到NASH的进展中至关重要.
研究的目的:
- 审查有关非酒精性脂肪肝炎 (NASH) 的当前研究.
- 确定新兴的药物治疗方法和NASH治疗的治疗点.
- 用in silico方法分析药物标,以提高药物发现率.
主要方法:
- 关于NASH发展和进展的研究文献综述.
- 对新兴药物治疗方法和治疗目标的分析.
- 现有药物点的结构分析,用于体药物发现.
主要成果:
- 确定了NASH发展和进展的关键因素.
- 总结了NASH的新兴药物治疗方法和治疗目标.
- 提供了目标的结构分析,以帮助在体中发现药物.
结论:
- 目前的研究提供了NASH临床试验中的药理学剂的最新信息.
- 目前正在为NASH药物开发做大量的研究.
- 在NASH的综合药物开发中仍然存在差距和挑战.
更多相关视频
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
相关概念视频
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
